BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26620085)

  • 1. FGF23-S129F mutant bypasses ER/Golgi to the circulation of hyperphosphatemic familial tumoral calcinosis patients.
    Shawar SM; Ramadan AR; Ali BR; Alghamdi MA; John A; Hudaib FM
    Bone; 2016 Dec; 93():187-195. PubMed ID: 26620085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed.
    Larsson T; Davis SI; Garringer HJ; Mooney SD; Draman MS; Cullen MJ; White KE
    Endocrinology; 2005 Sep; 146(9):3883-91. PubMed ID: 15961556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
    Roberts MS; Burbelo PD; Egli-Spichtig D; Perwad F; Romero CJ; Ichikawa S; Farrow E; Econs MJ; Guthrie LC; Collins MT; Gafni RI
    J Clin Invest; 2018 Dec; 128(12):5368-5373. PubMed ID: 30226830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
    Folsom LJ; Imel EA
    Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis.
    Bergwitz C; Banerjee S; Abu-Zahra H; Kaji H; Miyauchi A; Sugimoto T; Jüppner H
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4267-74. PubMed ID: 19837926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
    Claramunt-Taberner D; Bertholet-Thomas A; Carlier MC; Dijoud F; Chotel F; Silve C; Bacchetta J
    Pediatr Nephrol; 2018 Jul; 33(7):1263-1267. PubMed ID: 29594503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
    Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
    Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
    Liu C; Pang Q; Jiang Y; Xia Y; Fang L; Wang O; Li M; Xing X; Gong Y; Xia W
    Bone; 2020 Aug; 137():115401. PubMed ID: 32360901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis.
    Garringer HJ; Malekpour M; Esteghamat F; Mortazavi SM; Davis SI; Farrow EG; Yu X; Arking DE; Dietz HC; White KE
    Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E929-37. PubMed ID: 18682534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel
    Zuo Q; Yang W; Liu B; Yan D; Wang Z; Wang H; Deng W; Cao X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():1008800. PubMed ID: 36213261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Simple Diagnostic Method to Detect Gain and Loss of Function Defects in Fibroblast Growth Factor-23.
    Ramadan AR; Shawar SM; Alghamdi MA
    Horm Res Paediatr; 2016; 86(1):45-52. PubMed ID: 27355663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
    Rafaelsen S; Johansson S; Ræder H; Bjerknes R
    BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
    Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
    J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
    Ito N; Fukumoto S
    Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation.
    Goldenstein PT; Neves PD; Balbo BE; Elias RM; Pereira AC; Onuchic LF; Jüppner H; Jorgetti V; Abensur H; Moysés RM
    Am J Kidney Dis; 2018 Sep; 72(3):457-461. PubMed ID: 29548779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.
    Shah A; Miller CJ; Nast CC; Adams MD; Truitt B; Tayek JA; Tong L; Mehtani P; Monteon F; Sedor JR; Clinkenbeard EL; White K; Mehrotra R; LaPage J; Dickson P; Adler SG; Iyengar SK
    Nephrol Dial Transplant; 2014 Dec; 29(12):2235-43. PubMed ID: 25378588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
    Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
    Garringer HJ; Fisher C; Larsson TE; Davis SI; Koller DL; Cullen MJ; Draman MS; Conlon N; Jain A; Fedarko NS; Dasgupta B; White KE
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4037-42. PubMed ID: 16868048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
    Vieira AR; Lee M; Vairo F; Loguercio Leite JC; Munerato MC; Visioli F; D'Ávila SR; Wang SK; Choi M; Simmer JP; Hu JC
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):e235-9. PubMed ID: 26337219
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.